Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SIX homeobox 6 (SIX6) is a homeobox transcription factor that plays a critical role in eye development, particularly in the regulation of retinal progenitor cell proliferation and differentiation. It is a member of the evolutionary conserved SIX family, defined by a homeobox DNA-binding domain and the SIX protein-protein interaction domain. SIX6 expression is essential for early retinal determination, and disruption results in significant eye malformations. Mutations in SIX6 are associated with congenital disorders such as microphthalmia with cataract type 2, and genetic variants have been linked to increased risk of primary open-angle glaucoma. While primarily acting as a regulator in embryogenesis and ocular development, aberrant expression or epigenetic regulation of SIX6 and related SIX family members has been implicated in oncogenesis, though SIX6 itself is not currently a direct therapeutic target.
Not applicable (no drugs specifically target SIX6 reported to date)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SIX homeobox 6 (SIX6).